HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis.
One hundred and forty-one patients with rheumatoid arthritis treated with aurothiopropanol sulphonate or D-penicillamine, or both were examined for HLA antigens to investigate the genetic influence on the occurrence of different adverse reactions during therapy. All 13 patients possessing HLA-DR3 had toxic reactions. The relative risk for DR3 positives of developing skin eruptions or proteinuria was calculated to be 10.5 times and seven times respectively that of DR3 negatives. The incidence of DR7 antigen in 94 patients with toxic reactions was significantly decreased (11% compared with 28% in controls) suggesting a protective role for this antigen.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004112:Dimercaprol / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006046:Gold / Q000009:adverse effects*; D006680:HLA Antigens / Q000276:immunology*; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015803:HLA-DR3 Antigen; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D050607:Organogold Compounds; D009942:Organometallic Compounds; D010396:Penicillamine / Q000009:adverse effects*; D020005:Propanols; D013438:Sulfhydryl Compounds
D000893:Anti-Inflammatory Agents; D006680:HLA Antigens; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D015803:HLA-DR3 Antigen; D000949:Histocompatibility Antigens Class II; D050607:Organogold Compounds; D009942:Organometallic Compounds; D020005:Propanols; D013438:Sulfhydryl Compounds; D004112:Dimercaprol; D006046:Gold; C013394:aurotioprol; D010396:Penicillamine